

Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents

Estimated Time to Complete Activity: 60 minutes

Credit Available

- 1.0 *AMA PRA Category 1 Credit(s)*[™] (Physician)
- 1.0 CNE Contact Hours (Nurses)
- 1.0 ACPE Contact Hours (Pharmacy)

Program Overview

Despite major advances in prophylaxis and supportive care, hemophilia continues to disrupt daily life, limit function, and compromise long-term well-being for many patients. Joint bleeding, subclinical bleeding, and progressive arthropathy remain important concerns, even in the modern treatment era, with ongoing impacts on pain, mobility, and health-related quality of life. Clinicians must keep pace with shifting treatment strategies, including updated factor VIII (FVIII) target levels from recent guidelines to mediate bleeding protection and the growing role of rebalancing agents. To deliver optimal care, healthcare professionals need a clearer understanding of how to preserve joint health across the lifespan, apply evolving treatment targets judiciously, and select and integrate therapies in ways that reflect the latest clinical evidence, patient priorities, and treatment burden. This activity addresses these needs through expert-led discussions focused on long-term joint outcomes, FVIII-targeted treatment strategies, and the practical clinical integration of rebalancing agents.

Learning Objectives

On completion of this activity, the learner will be better able to:

- Formulate strategies to address the joint health–related unmet needs of patients with hemophilia in clinical practice.
- Assess the impact of factor-based replacement therapies on FVIII levels according to the guidelines.
- Evaluate the safety and efficacy of newly approved rebalancing agents and implement integration strategies that support personalized, patient-focused hemophilia management.

Learning Goal

The goal of this activity is to equip learners with practical strategies to optimize joint health, apply evolving evidence and guidance related to FVIII levels, and integrate rebalancing agents into individualized, patient-centered hemophilia care.

Faculty

Moderator

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disease Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Faculty (3 total)

Annette von Drygalski, MD, PharmD, RMSK

Professor of Clinical Medicine
Director, Center for Bleeding and Clotting Disorders
Associate Director, Center of Excellence for Hereditary Hemorrhagic Telangiectasia
Program Director, Coagulation Medicine Fellowship
Associate Program Director, Hematology Fellowship
University of California, San Diego
San Diego, California

Steven Pipe, MD

Professor of Pediatrics and Pathology
Laurence A. Boxer Research Professor of Pediatrics
University of Michigan
Ann Arbor, Michigan

Robert Sidonio Jr, MD, MSc

Professor of Pediatrics
Emory University School of Medicine
Medical Director
Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders of Emory
Atlanta, GA

Target Audience

The audience for this educational initiative is physicians, advanced practice clinicians, and pharmacists who care for individuals with hemophilia.

This activity is jointly provided by Partners for Advancing Clinical Education (Partners) and CMEology.



This activity is supported by an independent educational grant from Sanofi.

Joint Accreditation



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and CMEology. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate

Pharmacy Continuing Education

Partners designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008073-9999-26-130-H01-P)
Type of Activity: Knowledge

Disclosure of Conflict of Interest

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty	Conflicts of Interest
Dr. Young	<i>Consultant, Advisor, Speaker:</i> BioMarin, CSL Behring, Genentech, Hema, Novo Nordisk, Octapharma, Pfizer, Sanofi.
Dr. von Drygalski	<i>Consultant, Advisor, Speaker:</i> CSL Behring, Genentech, Novo Nordisk, Pfizer, Sanofi, Takeda. <i>Cofounder:</i> Hematherix LLC
Dr. Pipe	<i>Consultant, Advisor, Speaker:</i> Bayer, BioMarin, CSL Behring, HEMA Biologics, Inovio, LFB, Metagenomi, Novo Nordisk, Pfizer, Regeneron, Roche/Genentech, Sanofi, Spark Therapeutics, Takeda, Werfen.
Dr. Sidonio	<i>Researcher:</i> Sanofi/Sobi <i>Consultant, Advisor, Speaker:</i> Bayer, LFB/HEMA Biologics, Novo Nordisk, Octapharma, Pfizer, Star, Takeda.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturers’ product information, and comparison with recommendations of other authorities.

Instructions

Participation in this self-study activity should be completed in approximately 60 minutes. To successfully complete this activity and receive CE credit, learners must follow these steps:

1. Review the objectives and disclosures
2. Study the educational content

3. Successfully complete activity post-test(s)

4. Complete the activity evaluation

In order to receive CME/CE credits, participants must complete the post-assessment and program evaluation. Participants must also score at least 70% on the post-assessment. Certificates will be distributed online at the conclusion of the activity.

Computer System Hardware/Software Requirements

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.

For additional information about the accreditation of this activity, please visit <https://partnersed.com>.